What it is
AOD-9604 is a modified fragment of the C-terminal region of human growth hormone. It was developed to study fat metabolism separately from the other actions of full-length growth hormone.
What the research says
- In obese mice, chronic treatment with a growth hormone C-terminal fragment was reported to change fat metabolism [1].
- A related mouse study examined effects on lipid metabolism, including in animals lacking the beta-3 adrenergic receptor [2].
- We did not find peer-reviewed human trial results for AOD-9604 in the sources we reviewed.
Regulatory status
AOD-9604 is research-stage. It is not FDA approved for any use, and compounded versions are not FDA approved. Where prescribed, compounded versions are prepared by state-licensed 503A compounding pharmacies.
Safety and side effects
We did not find peer-reviewed human safety data for AOD-9604. Animal studies cannot show what side effects occur in people. A licensed healthcare provider should review your history, medications and goals.
Is it right for you?
Only a licensed healthcare provider can decide whether any treatment is appropriate for you.
Frequently asked questions
What do studies say about AOD-9604?
Animal studies reported changes in fat metabolism [1][2]. We did not find peer-reviewed human trial results.
Is AOD-9604 approved by FDA?
No. AOD-9604 is not FDA approved and is research-stage. Compounded versions are not FDA approved.
Do I need a prescription for AOD-9604?
Yes. Prescription only, requires evaluation by a licensed provider. A provider decides whether it is appropriate for you.
Sources
- Heffernan MA, et al. Int J Obes Relat Metab Disord, 2001 (mouse study; PubMed 11673763). https://pubmed.ncbi.nlm.nih.gov/11673763/
- Heffernan M, et al. Endocrinology, 2001 (mouse study; PubMed 11713213). https://pubmed.ncbi.nlm.nih.gov/11713213/
AOD-9604 content on this page is for education. Compounded medications are not FDA approved. Prescription only, requires evaluation by a licensed provider. Educational content only, not medical advice.